Prognostic impact of monocyte count at presentation in mantle cell lymphoma

Abstract

Summary An increased number of circulating monocytes at presentation has recently been associated with shorter survival in Hodgkin lymphoma, follicular lymphoma and diffuse large B cell lymphoma. This study aimed to assess the prognostic impact of the absolute monocyte count (AMC) at diagnosis in mantle cell lymphoma (MCL). AMC at diagnosis was available in 97 MCL cases recorded in the databases of the Oncology Institute of Southern Switzerland in Bellinzona (Switzerland) and the Division of Haematology of the Amedeo Avogadro University of Eastern Piedmont in Novara (Italy). With a median follow up of 7 years, the 5‐year overall survival was 29% for patients with AMC >0·50 × 109/l and 62% for patients with AMC ≤0·50 × 109/l (P = 0·008). Elevated AMC and beta‐2 microglobulin at diagnosis remained independent outcome predictors at multivariate analysis, controlling for the MCL International Prognostic Index (MIPI), and have been used to build a simple prognostic scoring system. In this relatively small and heterogeneous series an increased AMC identified poor‐risk patients. Our results suggest that AMC together with the beta‐2 microglobulin level might provide an inexpensive way to stratify MCL patient risk as a complement to the MIPI, which was confirmed to be a very powerful prognostic tool.

Serum beta-2 microglobulin as a prognostic biomarker in patients with mantle cell lymphoma

“…Although that analysis was based on a very small number of patients (27 were available for serum B2M), there was a huge difference reported in long‐term survival, with a 5‐year OS rate of 100% in patients with serum B2M ≤3 mg/L vs 22% in those with serum B2M >3 mg/L . In a previous study aimed to assess the prognostic impact of AMC for patients with MCL, serum B2M was also an independent prognostic factor .…”

Involvement of tumor-associated macrophage activationin vitroduring development of a novel mantle cell lymphoma cell line, PF-1, derived from a typical patient with relapsed disease

“…Virtually every other histotype of B-cell NHL and Hodgkin disease has now been shown to have significant macrophage component interactions that often show clinical significance [24]. More recent studies have shown that a high monocyte count at presentation in MCL can predict poor clinical outcomes [25,26]. The postulated mechanism for this relationship is that high monocyte count is a surrogate biomarker of the tumor microenvironment, reflecting the recruited peripheral blood immunosuppressive monocytes by the tumor transforming into tumor-associated macrophages, leading to cancer progression.…”

Peripheral blood lymphocyte-to-monocyte ratio as a prognostic factor in advanced epithelial ovarian cancer: a multicenter retrospective study

“…Absolute lymphocyte count was proven to be an independent prognostic factor in bladder cancer, melanoma and extranodal natural killer/T-cell lymphoma 8-10. Elevated monocyte count has been demonstrated to predict poor prognosis in mantle cell lymphoma, colorectal cancer and lung adenocarcinoma 11-13. Lymphocyte-to-monocyte ratio (LMR) has been shown to be a prognostic factor for patients with hepatocellular carcinoma and endometrial cancer 14, 15.…”